dpp-4 inhibitor and glp-1 receptor agonist combination versus kidney and cardiovascular outcomes in clinical practice in type-2 diabetes GLP-1 receptor agonists and DPP-4

Description

In vivo assessment of high-fat-fed Trpm5 / mice demonstrated the absence of triagonist-induced therapeutic effects on glycaemic management

Together, these inputs help preserve lean mass during periods of weight change

Both the FDA and the European Medicines Agency are also now considering the approval of semaglutide for the treatment of chronic kidney diseases in patients with type 2 diabetes (Manalac, June 2024

The emergence of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists has reshaped DKD management

At our clinic in Skudai, Johor , we provide a structured medical programme to ensure your safety: Safety Screening: We assess your medical history, including thyroid health and current medications, before recommending treatment